Andreas Jekle

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2115299/publications.pdf

Version: 2024-02-01

33 papers	1,611 citations	471509 17 h-index	395702 33 g-index
36 all docs	36 docs citations	36 times ranked	2100 citing authors

#	Article	IF	Citations
1	ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits inÂvivo efficacy in a Syrian Hamster model. Biochemical and Biophysical Research Communications, 2021, 555, 134-139.	2.1	30
2	Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry. Antiviral Research, 2020, 182, 104924.	4.1	33
3	Synthesis and Anti-HCV Activity of Sugar-Modified Guanosine Analogues: Discovery of AL-611 as an HCV NS5B Polymerase Inhibitor for the Treatment of Chronic Hepatitis C. Journal of Medicinal Chemistry, 2020, 63, 10380-10395.	6.4	18
4	Regulation of gene transcription by thyroid hormone receptor Î² agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH). PLoS ONE, 2020, 15, e0240338.	2.5	17
5	Synthesis and Anti-HCV Activities of 4â€²-Fluoro-2â€²-Substituted Uridine Triphosphates and Nucleotide Prodrugs: Discovery of 4â€²-Fluoro-2â€²-C-methyluridine 5â€²-Phosphoramidate Prodrug (AL-335) for the Treatment of Hepatitis C Infection. Journal of Medicinal Chemistry, 2019, 62, 4555-4570.	6.4	34
6	Structure-activity relationship analysis of mitochondrial toxicity caused by antiviral ribonucleoside analogs. Antiviral Research, 2017, 143, 151-161.	4.1	41
7	Synthesis and Anti-Influenza Activity of Pyridine, Pyridazine, and Pyrimidine C-Nucleosides as Favipiravir (T-705) Analogues. Journal of Medicinal Chemistry, 2016, 59, 4611-4624.	6.4	74
8	Sulfonyl-polyol N,N-dichloroamines with rapid, broad-spectrum antimicrobial activity. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 5650-5653.	2.2	4
9	Broad-Spectrum Virucidal Activity of (NVC-422)N,N-dichloro-2,2-dimethyltaurine against Viral Ocular Pathogens In Vitro. , 2013, 54, 1244.		5
10	NVC-422 Inactivates Staphylococcus aureus Toxins. Antimicrobial Agents and Chemotherapy, 2013, 57, 924-929.	3.2	10
11	Nâ€chlorotaurine and its analogues N,Nâ€dichloroâ€2,2â€dimethyltaurine and Nâ€monochloroâ€2,2â€dimethyltaurine are safe and effective bactericidal agents in ex vivo corneal infection models. Acta Ophthalmologica, 2012, 90, e632-7.	1.1	5
12	Efficacy of NVCâ€422 against Staphylococcus aureus biofilms in a sheep biofilm model of sinusitis. International Forum of Allergy and Rhinology, 2012, 2, 309-315.	2.8	17
13	Development of Tetravalent, Bispecific CCR5 Antibodies with Antiviral Activity against CCR5 Monoclonal Antibody-Resistant HIV-1 Strains. Antimicrobial Agents and Chemotherapy, 2011, 55, 2369-2378.	3.2	73
14	Virucidal mechanism of action of NVC-422, a novel antimicrobial drug for the treatment of adenoviral conjunctivitis. Antiviral Research, 2011, 92, 470-478.	4.1	16
15	Biochemical characterization of the inhibition of the dengue virus RNA polymerase by beta-d-2â€²-ethynyl-7-deaza-adenosine triphosphate. Antiviral Research, 2010, 87, 213-222.	4.1	39
16	Evaluation of secondary amide replacements in a series of CCR5 antagonists as a means to increase intrinsic membrane permeability. Part 1: Optimization of gem-disubstituted azacycles. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 704-708.	2.2	16
17	Evaluation of a 4-aminopiperidine replacement in several series of CCR5 antagonists. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 1830-1833.	2.2	9
18	Novel hexahydropyrrolo[3,4-c]pyrrole CCR5 antagonists. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 3116-3119.	2.2	9

#	Article	IF	Citations
19	Synthesis, SAR and evaluation of [1,4â€²]-bipiperidinyl-4-yl-imidazolidin-2-one derivatives as novel CCR5 antagonists. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 3219-3222.	2.2	11
20	Exploration of a new series of CCR5 antagonists: Multi-dimensional optimization of a sub-series containing N-substituted pyrazoles. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 4753-4756.	2.2	4
21	Evaluation of amide replacements in CCR5 antagonists as a means to increase intrinsic permeability. Part 2: SAR optimization and pharmacokinetic profile of a homologous azacyle series. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 6802-6807.	2.2	4
22	Epitope Switching as a Novel Escape Mechanism of HIV to CCR5 Monoclonal Antibodies. Antimicrobial Agents and Chemotherapy, 2010, 54, 734-741.	3.2	4
23	CD4-anchoring HIV-1 Fusion Inhibitor with Enhanced Potency and in Vivo Stability. Journal of Biological Chemistry, 2009, 284, 5175-5185.	3.4	24
24	CD4-BFFI: A novel, bifunctional HIV-1 entry inhibitor with high and broad antiviral potency. Antiviral Research, 2009, 83, 257-266.	4.1	11
25	Spiropiperidine CCR5 antagonists. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5401-5406.	2.2	22
26	Closing two doors of viral entry: Intramolecular combination of a coreceptor- and fusion inhibitor of HIV-1. Virology Journal, 2008, 5, 56.	3.4	24
27	Novel CCR5 monoclonal antibodies with potent and broad-spectrum anti-HIV activities. Antiviral Research, 2007, 74, 125-137.	4.1	35
28	A Novel Potassium Channel in Lymphocyte Mitochondria. Journal of Biological Chemistry, 2005, 280, 12790-12798.	3.4	188
29	In Vivo Evolution of Human Immunodeficiency Virus Type 1 toward Increased Pathogenicity through CXCR4-Mediated Killing of Uninfected CD4 T Cells. Journal of Virology, 2003, 77, 5846-5854.	3.4	118
30	Actinomycin D-induced apoptosis involves the potassium channel Kv1.3. Biochemical and Biophysical Research Communications, 2002, 295, 526-531.	2.1	70
31	Coreceptor Phenotype of Natural Human Immunodeficiency Virus with Nef Deleted Evolves In Vivo, Leading to Increased Virulence. Journal of Virology, 2002, 76, 6966-6973.	3.4	42
32	CD95 Signaling via Ceramide-rich Membrane Rafts. Journal of Biological Chemistry, 2001, 276, 20589-20596.	3.4	559
33	CD95/CD95 Ligand-Mediated Counterattack Does Not Block T Cell Cytotoxicity. Biochemical and Biophysical Research Communications, 2000, 272, 395-399.	2.1	3